Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, FDA announced plans for a pilot program to allow for real-time data review ...
Biotech’s ~10-year path from private risk to approved therapy is mismatched with trading-driven capital markets, where minor ...
David Crean, chief business officer at MedicNova, discusses changes at FDA causing variability and unpredictability in ...
In the third part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, traces the origins of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results